Meiragtx Holdings PLC (MGTX) — SEC Filings

Overview

Meiragtx Holdings PLC (MGTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 24, 2026: On August 2, 2022, Joseph Edelman, a reporting person associated with Perceptive Advisors LLC, reported a change in beneficial ownership of securities for MeiraGTx Holdings plc. The filing details transactions related to these securities, but specific dollar amounts and the exact nature of the trans

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 3 bearish, 29 neutral, 3 mixed. The dominant filing sentiment for Meiragtx Holdings PLC is neutral.

Filing Type Overview

Meiragtx Holdings PLC (MGTX) has filed 2 4, 1 144, 13 8-K, 3 10-K, 6 10-Q, 2 DEF 14A, 5 SC 13G/A, 2 SC 13D/A, 1 8-K/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (35)

• Insider Ownership Change at MeiraGTx Holdings — 4 · Apr 24, 2026 Risk: low
  On August 2, 2022, Joseph Edelman, a reporting person associated with Perceptive Advisors LLC, reported a change in beneficial ownership of securities for Meira
• 8-K Filing — 8-K · Apr 16, 2026
• MeiraGTx Pivots from IRDs, Focuses on Riboswitch Platform — 10-K · Mar 30, 2026 Risk: high
  MeiraGTx Holdings plc (MGTX) is a clinical-stage genetic medicines company with a broad pipeline, including programs for radiation-induced xerostomia, Parkinson
• MeiraGTx Enters Material Agreement, Takes on New Financial Obligation — 8-K · Mar 26, 2026
  MeiraGTx Holdings plc filed an 8-K on March 26, 2026, detailing an "Entry into a Material Definitive Agreement" and "Creation of a Direct Financial Obligation."
• MeiraGTx Insider Forbes Alexandria Reports Ownership Change — 4 · Mar 25, 2026
  This Form 4 filing, dated March 24, 2026, indicates a change in beneficial ownership for Forbes Alexandria, a reporting person associated with MeiraGTx Holdings
• Forbes Alexandria Files to Sell MeiraGTx Holdings plc Securities — 144 · Mar 25, 2026
  This 144 filing indicates that Forbes Alexandria, a reporting entity, intends to sell securities of MeiraGTx Holdings plc (CIK: 0001735438). The filing was acce
• MeiraGTx's Cash Dries Up Amid Widening Losses, Revenue Halves — 10-Q · Nov 13, 2025 Risk: high
  MeiraGTx Holdings plc reported a significant increase in net loss for the nine-month period ended September 30, 2025, reaching $129.289 million, up from $108.39
• MeiraGTx Holdings plc Files 8-K for Material Agreement — 8-K · Nov 10, 2025 Risk: medium
  MeiraGTx Holdings plc entered into a material definitive agreement on November 7, 2025. The company, incorporated in the Cayman Islands with principal executive
• MeiraGTx Losses Widen to $78.8M Amid Cash Burn, Hologen Deal Offers Lifeline — 10-Q · Aug 14, 2025 Risk: high
  MeiraGTx Holdings plc reported a net loss of $78.776 million for the six months ended June 30, 2025, an increase from a net loss of $69.062 million in the prior
• MeiraGTx Holdings plc Files 8-K for Regulation FD Disclosure — 8-K · Jun 26, 2025 Risk: low
  MeiraGTx Holdings plc filed an 8-K on June 26, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material ev
• MeiraGTx Holdings plc Files 8-K on Shareholder Votes — 8-K · Jun 17, 2025 Risk: low
  MeiraGTx Holdings plc filed an 8-K on June 17, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing details the co
• MeiraGTx Holdings plc Q1 2025 10-Q Filing — 10-Q · May 13, 2025 Risk: medium
  MeiraGTx Holdings plc filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $790.3 million and total liabilities of $64.1 mi
• MeiraGTx Holdings plc Files 8-K — 8-K · May 9, 2025 Risk: low
  MeiraGTx Holdings plc filed an 8-K on May 9, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain speci
• MeiraGTx Holdings plc Executive Compensation Details — DEF 14A · Apr 30, 2025 Risk: medium
  MeiraGTx Holdings plc filed a DEF 14A on April 30, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes info
• MeiraGTx Holdings plc Enters and Terminates Agreements — 8-K · Apr 4, 2025 Risk: medium
  On March 31, 2025, MeiraGTx Holdings plc entered into a material definitive agreement and terminated another. The company, incorporated in the Cayman Islands wi
• MeiraGTx Holdings plc Files 2024 10-K — 10-K · Mar 13, 2025 Risk: medium
  MeiraGTx Holdings plc filed its 2024 10-K on March 13, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, focu
• MeiraGTx Holdings plc Files 8-K — 8-K · Dec 9, 2024 Risk: low
  MeiraGTx Holdings plc filed an 8-K on December 9, 2024, to report other events and financial statements. The filing does not contain specific details about new
• MeiraGTx Holdings plc Files Q3 2024 10-Q — 10-Q · Nov 13, 2024 Risk: medium
  MeiraGTx Holdings plc filed a 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the company, w
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Oct 18, 2024
• MeiraGTx Holdings plc Files 8-K — 8-K · Oct 15, 2024 Risk: low
  MeiraGTx Holdings plc filed an 8-K on October 15, 2024, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other
• Perceptive Advisors Amends MeiraGTx Holdings Stake — SC 13D/A · Aug 14, 2024 Risk: medium
  Perceptive Advisors LLC, through Perceptive Life Sciences Master Fund, Ltd. and Joseph Edelman, has amended its Schedule 13D filing for MeiraGTx Holdings plc. T
• SC 13G/A Filing — SC 13G/A · Aug 13, 2024
• MeiraGTx Holdings plc Files 8-K Report — 8-K · Aug 13, 2024 Risk: low
  MeiraGTx Holdings plc filed an 8-K on August 13, 2024, reporting on events that occurred on August 12, 2024. The filing is a current report pursuant to Section
• MeiraGTx Holdings plc Q2 2024 10-Q Filing — 10-Q · Aug 12, 2024 Risk: medium
  MeiraGTx Holdings plc filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $643.8 million and total liabilities of $55.3 mil
• MeiraGTx Holdings plc Announces AGM Date — 8-K · Jun 10, 2024 Risk: low
  MeiraGTx Holdings plc announced on June 6, 2024, that it will hold its Annual General Meeting (AGM) on July 10, 2024. Shareholders will vote on the re-election
• MeiraGTx Holdings plc Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
  MeiraGTx Holdings plc (MGTX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. MeiraGTx Holdings plc filed a 10-Q report for the period ending March
• MeiraGTx Holdings plc Announces 2024 Annual General Meeting — DEF 14A · Apr 25, 2024 Risk: low
  MeiraGTx Holdings plc (MGTX) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. MeiraGTx Holdings plc will hold its 2024 Annual General Meeting o
• MeiraGTx Holdings plc Files 8-K/A Amendment — 8-K/A · Apr 16, 2024 Risk: low
  MeiraGTx Holdings plc filed an amendment (8-K/A) on April 16, 2024, related to events on April 25, 2022. The filing concerns the departure of directors or certa
• MeiraGTx Holdings plc Files 2023 Annual Report on Form 10-K — 10-K · Mar 15, 2024 Risk: medium
  MeiraGTx Holdings plc (MGTX) filed a Annual Report (10-K) with the SEC on March 15, 2024. MeiraGTx Holdings plc reported total assets of $564,865,250 as of Dece
• MeiraGTx Holdings plc Files 8-K — 8-K · Mar 14, 2024 Risk: low
  MeiraGTx Holdings plc filed an 8-K on March 14, 2024, reporting on its results of operations and financial condition, as well as filing financial statements and
• Perceptive Advisors Amends MeiraGTx Holdings Stake — SC 13D/A · Feb 14, 2024 Risk: medium
  Perceptive Advisors LLC, along with group members Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., filed an Amendment No. 5 to their Schedule 13D
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• MeiraGTx Files 8-K for Unspecified Other Events and Exhibits — 8-K · Feb 13, 2024 Risk: low
  MeiraGTx Holdings plc filed an 8-K current report with the SEC on February 13, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filin
• Adage Capital Partners Cuts MeiraGTx Stake to 5.0% — SC 13G/A · Feb 7, 2024
  Adage Capital Partners, L.P. filed an amended Schedule 13G/A on February 7, 2024, disclosing its beneficial ownership in MeiraGTx Holdings plc as of December 31

Risk Profile

Risk Assessment: Of MGTX's 26 recent filings, 3 were flagged as high-risk, 10 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Joseph Edelman
• Alexander Rakitin

Industry Context

MeiraGTx operates in the rapidly evolving genetic medicines sector, characterized by significant scientific advancements and increasing investment. The industry is highly competitive, with a focus on developing therapies for rare genetic disorders and expanding into more prevalent diseases. Key trends include advancements in gene editing technologies, novel delivery systems, and the development of manufacturing platforms to support commercial scale-up.

Top Tags

Gene Therapy (4) · Biotechnology (4) · 10-Q (4) · financials (4) · ownership-change (3) · Clinical Stage (3) · material-agreement (3) · biotechnology (3) · corporate-governance (3) · regulatory-filing (3)

Key Numbers

• Upfront fee: $100.0M — Received from Johnson & Johnson Innovative Medicine in March 2019 for Collaboration Agreement
• Milestone payment: $30.0M — Received from Johnson & Johnson Innovative Medicine in December 2021 for Collaboration Agreement
• London facility size: 29,000 sq ft — Flexible and scalable viral vector manufacturing facility
• Shannon campus size: 150,000 sq ft — Large scale GMP viral vector and plasmid manufacturing facility
• Commercial MIA granted: December 2025 — London manufacturing facility received commercial Manufacturer's and Importer's Authorization
• Ordinary shares outstanding: 81,446,126 — As of March 30, 2026
• Market value of non-affiliate shares: $524,509,772 — As of June 30, 2025
• Net Loss: $129.289M — Increased from $108.392M in 2024 for the nine-month period, indicating worsening profitability.
• Cash and Cash Equivalents: $14.841M — Decreased significantly from $103.659M at December 31, 2024, highlighting a severe liquidity crunch.
• Total Revenue: $6.027M — Halved from $11.889M in 2024 for the nine-month period, showing a substantial decline in income.
• Net Cash Used in Operating Activities: $92.990M — For the nine months ended September 30, 2025, demonstrating high operational cash burn.
• Total Shareholders' Equity: $(40.557)M — Shifted from a positive $67.827M to a deficit, indicating a negative book value.
• Research and Development Expenses: $98.807M — Increased from $95.499M in 2024, reflecting continued investment in pipeline despite financial strain.
• Ordinary Shares Outstanding: 80,490,889 — As of October 28, 2025, indicating potential dilution from prior offerings.
• Total Current Liabilities: $152.922M — Increased from $60.783M, largely due to a reclassified note payable, signaling short-term debt pressure.

Related Companies

JNJ

Frequently Asked Questions